XML 53 R44.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT REPORTING (Details) - USD ($)
 3 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]    
Research and development $ 524,368 $ 414,658
General and administrative 735,358 751,974
Cash used in operating activities (1,714,937) (1,747,537)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Research and development [1] 524,000 415,000
General and administrative [2] 735,000 752,000
Cash used in operating activities [3] $ 1,715,000 $ 1,748,000
[1] Research and development expenses primarily include costs related to laboratory operations, clinical trial execution, investigational device testing, design iterations, and personnel expenses associated with research activities. These expenses may appear across different financial statement line items—such as general and administrative expense, professional fees, or payroll—but are monitored internally by the CODM as a single category.
[2] General and administrative expenses encompass overhead, clinical trial-related administrative and planning expenses, and certain manufacturing-related costs such as raw materials. These costs are not broken down further for internal reporting purposes and are reviewed as a whole.
[3] Cash used in operating activities is the key internal performance metric tracked by the CODM to evaluate development progress, cash needs, and investment strategy in the absence of commercial revenue.